Innovative Psoriasis Treatment Reaches Major Milestone in Clinical Trial
Monday, 27 May 2024, 21:12
Innovative Psoriasis Treatment Success
The recent announcement from Innovent reveals that the clinical trial for Picankibart (IBI112) has yielded positive results in the treatment of severe plaque psoriasis.
Key Findings:
- Phase 3 Milestone: The drug has achieved its primary endpoints, showcasing its efficacy in managing the skin condition.
- Regulatory Path: Innovent plans to submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA) for approval.
This development signifies a significant advancement in the field of dermatology, offering new hope for patients battling moderate to severe psoriasis.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.